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Key Points
• A drop in platelet count
.25% relative to
baseline at 6 months
from diagnosis predicts
inferior outcome in
lower-risk MDS.
• Platelet drop combined
with RBC-TD at
6 months provides an
inexpensive and
validated classifier of
outcome in lower-risk
MDS.
Prognosis of lower-risk (International Prognostic Scoring System [IPSS] low/intermediate-1)
myelodysplastic syndrome (MDS) is heterogeneous and relies on steady-state assessment of
cytopenias. We analyzed relative drops in neutrophil and platelet counts during the ﬁrst
6 months of follow-up of lower-risk MDS patients. We performed a landmark analysis of
overall survival (OS) of lower-risk MDS patients prospectively included in the European
LeukaemiaNet MDS registry having a visit at 6 6 1 month from inclusion to assess the
prognostic relevance of relative drops in neutrophils and platelets, deﬁned as (count at
landmark 2 count at inclusion)/count at inclusion. Of 2102 patients, 807 were eligible for
the stringent 6-month landmark analysis. Median age was 73 years. Revised IPSS was
very low, low, and intermediate/higher in 26%, 43%, and 31% of patients, respectively.
A relative drop in platelets .25% at landmark predicted shorter OS (5-year OS, 21.9% vs
48.6% with platelet drop #25%, P , 1024), regardless of baseline IPSS-revised or absolute
platelet counts. Relative neutrophil drop .25% had no signiﬁcant impact on OS. We built a
classiﬁer based on red blood cell transfusion dependence (RBC-TD) and relative platelet
drop .25% at landmark. Patients with none (62%), either (27%), or both criteria (11%) had
5-year OS of 53.3%, 32.7%, and 9.0%, respectively (P , 1024). This classiﬁer was validated
in an independent cohort of 335 patients. Combining relative platelet drop .25%
and RBC-TD at 6 months from diagnosis provides an inexpensive and noninvasive way
to predict outcome in lower-risk MDS. This study was registered at www.clinicaltrials.gov
as #NCT00600860.
Submitted 2 May 2018; accepted 6 July 2018. DOI 10.1182/
bloodadvances.2018020495.
Presented in part at the 59th annual meeting of the American Society of Hematology,
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Introduction
The prognosis of myelodysplastic syndromes (MDSs) defined as
“lower-risk” per classical International Prognostic Scoring System
(IPSS) criteria (IPSS low and intermediate-1) is heterogeneous.1
IPSS and revised IPSS (IPSS-R) rely on simple parameters, including
complete blood count (CBC), bone marrow (BM) cytopathology, and
cytogenetics.2 Flow cytometry or genomics could refine the prognosis
of lower-risk MDS,3-5 but these techniques are limited by their cost
and wide availability across health care systems. Time-dependent
prognostic scores, applicable at any time during disease evolution,
are helpful.6 However, they require repeated BM examinations,
whose timing is not standardized, raising acceptability issues in
this older patient population.
All current MDS prognostic scores rely on steady-state assessments
of cytopenias (ie, hemoglobin [Hb] level or neutrophil or platelet
counts) on the day of assessment. Conversely, the dynamics of
tumor markers is instrumental in the prognostication of various
malignancies.7,8 Here, we analyze, for the first time, the prognostic
role of the kinetics of cytopenias during the first months following
diagnosis in lower-risk MDS patients prospectively included in the
European LeukaemiaNet MDS (EUMDS) registry.9 We performed
a landmark analysis at 6 months from diagnosis to order simple
prognostic criteria directly applicable in clinical practice.
Patients and methods
Patients
Since December 2007, patients from 16 European countries and
Israel were included in the EUMDS registry, after signed informed
consent according to the Declaration of Helsinki, within 100 days
of the diagnosis of an MDS according to World Health Organization
(WHO) 2001 criteria10 and with an IPSS risk of low or intermediate-1.1
Patients with an IPSS risk of intermediate-2 or high or with therapy-
related MDS were excluded. Patients with cytogenetics failure, or
without available cytogenetics were included if the diagnosis of MDS
was morphologically proven, with ,5% BM blasts and, at most, a
single cytopenia according to IPSS. A post hoc central morphology
review confirmed the accuracy of MDS diagnoses in the registry.11
The registry was approved by each institution’s ethics committee,
according to the legislation of each country. It is registered at
www.clinicaltrials.gov with the identifier NCT00600860.
Data collection, follow-up, and end points
Data were collected through a Web-based interface. Blast count
was based on the local assessment of BM aspirates or, when
unavailable, of BM biopsies.11 IPSS cytogenetic category was
determined locally, whereas IPSS-R cytogenetic risks were retro-
spectively verified by an expert (D. Haase). IPSS and IPSS-R scores
were computed automatically based on centralized data.
Patient-specific (including CBC) intervention and outcome data
were collected at baseline and at each visit, which were to be
repeated at 6-month intervals. Red blood cell transfusion de-
pendence (RBC-TD) at any time point was defined as a requirement
of $2 red blood cell units in the 8 weeks preceding the visit. There
was no recommendation with respect to the timing of repeat BM
evaluations. Interventions were based on each center’s routine care
without guidelines from the registry.
All patients were prospectively followed until death, progression to
higher-risk MDS (defined as IPSS risk intermediate-2/high), or
transformation to acute myeloid leukemia per WHO criteria,10 until
the last follow-up, or withdrawal of informed consent.
The present substudy was based on the 2102 patients included
in the registry as of September 2016. The CONSORT diagram
of the study population is reported in supplemental Figure 1.
Inclusion criteria for the 6-month landmark analysis were a study
visit at 6 months 6 30 days of study entry, available platelet
counts at study entry and 6-month visit, and follow-up beyond
the 6-month visit.
External validation cohort
The external validation cohort was extracted from the Pavia Registry,
which accrued patients from 1992 to 20166,12 with the following
criteria: diagnosis of an MDS according to WHO 2001 criteria10
with an IPSS risk of low or intermediate-1,1 and available CBC
and information on RBC-TD at 6 6 1 months from diagnosis.
All definitions were identical to those used in EUMDS registry
patients. Patients already included in the EUMDS registry were
excluded from this validation cohort.
Statistical analyses
Continuous and categorical variables are described as medians
and interquartile ranges (IQRs) and number and percentages,
respectively. Equality of variance between different continuous
variables was assessed by the F test (variance ratio test). Group
comparisons for categorical and continuous variables were done
with x2 tests and Student t tests, respectively. Monotonic correla-
tions between continuous variables were investigated with Spearman
correlation tests, with graphical description of linear regression and
its 95% confidence interval (CI).
Relative platelet and neutrophil drop were defined as: ðcount at
landmark 2 count at inclusionÞ=count at inclusion:Rates of relative
platelet and neutrophil drops were defined as: relative platelet ðor
neutrophilÞ drop=interval between inclusion and landmark:
Multivariate analyses of factors associated with relative platelet and
neutrophils drops above or below defined thresholds were performed
by logistic regression, excluding the 41 patients having received blood
count–modifying treatments (hypomethylating agents [HMAs, n 5 16],
lenalidomide [LEN, n 5 22], or hydroxyurea [HY, n 5 3]) between
inclusion and landmark analysis.
For the landmark analyses, overall survival (OS) was estimated with
the Kaplan-Meier method from the day of landmark visit censoring
at last follow-up, considering death as event. Follow-up duration
from the date of diagnosis was determined according to the inverse
method.13 Cumulative incidence of progression (CIP) was calcu-
lated from landmark, considering progression to higher-risk MDS
(IPSS intermediate-2 or high risk) or acute myeloid leukemia AML
according to WHO criteria10 as events and considering death as a
competing risk. Differences in CIP between groups were assessed
with the Fine and Gray test.14
To dichotomize relative platelet and neutrophil drop, martingale
residuals of univariate Cox models of OS using relative platelet or
neutrophil drop as a continuous value were visually inspected. The
relevance of the retained cutoff was validated by comparing Akaike
information criteria (AIC) from univariate Cox models with continuous
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or dichotomized relative platelet (or neutrophil) drop.15 Sensitivity
analyses were performed using different thresholds for relative
platelet and neutrophil drops with 5% bins.
Univariate and multivariate analyses for OS were performed using
log-rank tests and Cox models, respectively. The proportional
hazard assumption was validated by graphical inspection of visual
display of the Scho¨nfeld residuals.16 Interactions were tested
by comparing Cox models, with or without an interaction term,
between the 2 variables analyzed through a likelihood ratio test, and
forest plots were plotted with the ipdmetan package for STATA.
Collinearity was estimated with variance inflation factors, retaining
the conventional variance inflation factor threshold of 4 as indica-
tive of unacceptable collinearity.17
Variable selection for multivariate Cox models was based on lasso
penalized regression, using the 1 standard error rule with the
glmnet package for R.18 All analyses were performed with STATA
12.0 (STATA Corporation, College Station, TX) or R version 3.3.2
(http://www.R-project.org) software.
Results
Landmark study population
From the first 2102 patients included in the registry, 807 fulfilled
the criteria for the 6-month landmark analysis (“landmark cohort”).
Characteristics of the landmark cohort at inclusion and at the
6-month visit are summarized in Table 1 and supplemental Table 1.
Median age was 73 years; 497 (61.6%) patients were male. IPSS-R
risk, available for 691 patients (85.6%), was very low, low, intermediate,
high, and very high in 26.0%, 43.0%, 24.2%, 6.1%, and 0.7% of
cases, respectively. The median interval between diagnosis and
landmark visit was 183 days.
Evolution of cytopenias
A total of 206 patients (25.5%) patients had RBC-TD ($2 red
blood cell units during the previous 8 weeks) prior to inclusion,
and 215 (26.6%) patients had RBC-TD at landmark, including
133 who already had RBC-TD at inclusion. Patients with RBC-TD
at landmark were more likely to receive erythropoiesis-stimulating
agent (ESA) compared with patients not transfused between
the 2 visits (ESA treatment in 45.1% and 30.4% of cases
respectively, P , 1024). The median absolute drop in platelet
count at landmark visit was 6 3 109/L (IQR of platelet change,
235 to 121), corresponding to a median relative drop of 4.6%
(IQR, 222.2% to 112.5%). At landmark, neutrophil count was
available in 774 patients. The median absolute and relative
neutrophil drops were 0.11 3 109/L (IQR, 20.76 to 10.49) and
5.2% (IQR, 229.2% to 129.7%) (supplemental Figure 2).
To investigate platelet and neutrophil drops as surrogates of BM
function irrespective of the risk for hemorrhage and infection, which
may differ for the same absolute platelet and neutrophil drop
depending on baseline values, we focused on relative drops
compared with baseline. There was a modest, yet significant,
correlation between 6-month changes in platelets and neutro-
phils (R2 5 10.048, P , 1024), but no correlation between time
to landmark and relative platelet or neutrophil drop (Spearman
correlation tests, P 5 .51 and P 5 .16, respectively; supple-
mental Figure 2). The use of rates of platelet or neutrophil drop,
by normalizing according to the interval between inclusion and
landmark did, not affect our findings (data not shown).
Table 1.Main characteristics of the landmark cohort (n 5 807) at
inclusion and landmark
Variable
Inclusion visit
(n 5 807)
6-mo landmark
visit
n or
median
% or
IQR
n or
median
% or
IQR
Sex
Male 497 61.6%
Female 310 38.4%
Age, y 73 67-79
WHO classification at diagnosis
RA 141 17.5%
RARS 139 17.2%
RCMD 309 38.3%
RCMD-RS 51 6.3%
5q2 syndrome 49 6.1%
RAEB-1 94 11.7%
RAEB-2 1 0.1%
MDS-U 23 2.9%
IPSS-R cytogenetic risk (n 5 730)
Very good 84 11.5%
Good 543 74.4%
Intermediate 89 12.1%
Poor/very poor 14 2.00%
IPSS-R risk (available in
691 patients*)
Very low 180 26.0%
Low 297 43.0%
Intermediate 167 24.2%
High 42 6.1%
Very high 5 0.7%
Hb level, g/dL 10.1 9-11.3
RBC-TD
No 601 74.5% 592 73.4%
Yes 206 25.5% 215 26.6%
Platelets, 3109/L 181 102-277 169 93-263
Neutrophils, 3109/L 2.4 1.4-3.9 2.3 1.4-3.7
Treatment before visit
ESA with or without G-CSF 115 14.2% 277 34.3%
G-CSF alone 2 0.3% 4 0.5%
HMA 1 0.1% 16 2.0%
HY 0 0% 3 0.4%
LEN 3 0.4% 22 2.7%
None 686 85% 485 60.1%
Time from diagnosis to inclusion, d 37 19-61
Time from inclusion to landmark, mo 6.1 5.7-6.4
Follow-up from landmark, mo 37.8 17.0-58.8
G-CSF, granulocyte colony-stimulating factor; MDS-U, MDS unclassified; RA, refractory
anemia; RAEB, refractory anemia with excess of blasts; RARS, refractory anemia with
ringed sideroblasts; RCMD, refractory cytopenia with multilineage dysplasia; RCMD-RD,
refractory cytopenia with multilineage dysplasia and ringed sideroblasts.
*Detailed cytogenetics missing in 77 patients; detailed BM blasts (total ,5%) missing in
39 patients.
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To exclude physiologic intrapatient variability in blood counts,19-21
we defined a .25% drop in platelets or in neutrophils over the first
6 months of follow-up as relevant cutoffs for prognostic analyses.
Relative platelet and neutrophil drops .25% were present in
21.7% and 29.1% of evaluable patients, respectively. A univariate
Cox model for OS using relative platelet or neutrophil drop did
not reveal any specific cutoff by visual inspection of martingale
residuals. AIC, a measure of information loss,15 was lower when
relative platelet drop was dichotomized at 25% compared with
the continuous variable (3540 and 3575, respectively). AIC for
continuous and dichotomized relative neutrophil drop was similar
(3372 and 3370, respectively).
Age, sex, BM (or peripheral blood) blasts, and cytogenetic risk
did not significantly influence early platelet drop (Table 2). Platelet
drop varied across diagnostic categories (P 5 .015) and was
more frequent in patients with intermediate IPSS-R risk or higher
(P 5 .024). Platelet drop was more frequent in the presence of
multilineage dysplasia (MLD; 67.9% vs 53.4% in the absence of
MLD, P 5 .005) but less frequent in MDS with ring sideroblasts
(21.3% vs 31.9% without ring sideroblasts, P5 .01). An increasing
number of cytopenias was associated with more frequent platelet
drop (P, 1024). Patients with lower baseline Hb levels (P, 1024)
and those with RBC-TD at inclusion (P , 1024) also had a platelet
drop . 25% more frequently, whereas baseline platelet count did
not affect relative platelet drop. Expectedly, treatment during the
first 6 months had a strong impact on platelet and neutrophil drops
(both P , 1024), especially in patients treated with HY, LEN, or
HMAs. In a multivariate logistic regression accounting for WHO,
number of cytopenias, RBC-TD, and baseline Hb level, RBC-TD
at inclusion stood out as the main determinant of early platelet drop
(odds ratio [OR], 1.7; 95% confidence interval [CI] 1.1-2.6, P 5 .02).
A 6-month drop in neutrophils.25% was more frequent in patients
with higher baseline neutrophil count (P, 1024) and was associated
with worse IPSS-R cytogenetic risk (P 5 .015). In a multivariate
regression, only a higher baseline neutrophil count (OR, 1.2;
95% CI, 1.1-1.4; P , 1024) maintained its predictive value
(supplemental Table 2), suggesting that the dynamic range of
neutrophils is not sufficient to capture meaningful changes in
patients with baseline neutropenia.
Prognostic relevance of early drop in platelets
and neutrophils
In the landmark cohort (n 5 807), with a median follow-up of 37.8
months, 5-year OS was 42.8% (95% CI, 37.6-47.9) and 5-year
CIP was 21.4% (95% CI, 17.8-25.0). Patients with a platelet drop
.25% had a 5-year OS of 21.9% (95% CI, 13.6-31.4) compared
with 48.6% (95% CI, 42.5-54.4) in patients with platelet drop
#25% (P , 1024; Figure 1). Five-year OS was 40.9% (95% CI,
30.7-50.8) in patients with a .25% neutrophil drop and 45.1%
(95% CI, 38.9-51.1) in those with a #25% drop (P 5 .12). CIP
was also higher in patients with platelet drop .25% (hazard ratio
[HR], 2.5; 95% CI, 1.7-3.7; P , 1024) and, to a lesser extent, with
neutrophil drop .25% (HR, 1.5; 95% CI, 1.0-2.2; P 5 .03; Figure 1).
Sensitivity analyses using different cutoff values for relative platelet and
neutrophil drop found a robust prognostic role for relative platelet
drop in OS across a large spectrum of thresholds (5%-40% relative
drop), whereas a significantly shorter OS was only found in patients
with a neutrophil drop .30% (data not shown). Because of the
stronger prognostic impact of platelet kinetics, we next focused on
the relevance of early platelet drop in defined subgroups.
Prognostic relevance of early platelet drop
in subgroups
Six-month relative platelet drop retained significant poor prognostic
value (HR, 2.1; 95% CI, 1.6-2.8; P , 1024) at landmark when
adjusting for IPSS-R risk at inclusion (HR, 1.1; 95% CI, 1.0-1.3;
P 5 .054). In subgroup analysis, there was no significant
interaction between IPSS-R risk and relative platelet drop (P 5 .4),
and 6-month platelet drop was associated with shorter OS in each
IPSS-R stratum (all P , .007; Figure 2). There were nonsignificant
interaction trends between relative platelet drop and baseline
(P 5 .1) or landmark platelet counts (P 5 .07). In particular, early
platelet drop had limited impact in the 221 (27.4%) patients with
a baseline platelet count ,50 3 109/L (P 5 .10) and a lower, but
nevertheless significant, impact in patients retaining a platelet count
.100 3 109/L at landmark (P 5 .051). Importantly, excluding the 45
patients (5.6%) having received HY, LEN, or HMAs during the 6-month
interval did not affect the poor prognosis of patients with a platelet
drop .25% and confirmed the prognostic relevance of platelet
drop in patients retaining platelets .100 3 109/L at landmark (HR,
1.6; 95% CI, 1.1-2.4; P 5 .023).
Sensitivity analysis of the timing of landmark
To generalize the finding that early platelet and, to a lesser extent,
neutrophil drop is associated with poor prognosis in lower-risk
MDS, we performed a sensitivity analysis by relaxing the inclusion
criteria for landmark analysis. All patients with a second visit within
10 months of registry inclusion with available platelet counts were
included, regardless of follow-up (supplemental Figure 1). This
“sensitivity cohort” included 1610 patients, with a median time to
second visit of 5.2 months (IQR, 4.1-6.1). Baseline characteristics
of this sensitivity cohort are summarized in supplemental Table 1.
Expectedly, time to landmark was much more variable in this
sensitivity cohort than in the 6-month landmark cohort (variance
ratio test: P , 1024; supplemental Figure 3).
In this sensitivity cohort, 340 (21.1%) patients had a.25% platelet
drop and 424 (26.3%) had a .25% neutrophil drop at landmark
visit. With a median follow-up of 40.9 months, the poor prognosis
of patients with platelet drop, as previously defined, was confirmed
in univariate analysis (HR, 2.3; 95% CI, 2.0-2.8; P , 1024;
supplemental Figure 4), and it remained strongly significant after
adjusting for baseline IPSS-R risk and platelet count at baseline or
at landmark (all P , 1024). In a sensitivity analysis considering the
rate of platelet decline, a decline in platelets of 4.2% per month
(corresponding to a 25% decline in 6 months) retained its prognostic
impact, even in patients assessed .6 months after the inclusion
visit (P5 .05). Time to second visit had no prognostic impact per se
(P 5 .12), also suggesting that the prognostic impact of platelet
decline is not due to a poorer outcome of patients with delayed
study visits.
Multivariate analysis of OS at the 6-month landmark
In the stringent landmark cohort of 807 patients, only 95 (11.8%)
patients had a control of BM blast percentage by aspirate or biopsy,
including 50 with informative cytogenetics, allowing stringent
reassessment of IPSS-R in only 6.2% of patients. Only 24 of the
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Table 2. Clinical and biological predictors of early platelet drop
Variable
Relative platelet drop
£25% (n 5 632) >25% (n 5 175)
P
Multivariate
n or median % or IQR n or median % or IQR OR 95% CI P
Sex .4
Male 394 62.3% 103 58.9%
Female 238 37.7% 72 41.1%
Age, y 73 67-79 73 66-79 .5
WHO classification at diagnosis .015
RA 113 17.9% 28 16.0% 1
RARS 122 19.3% 17 9.7% 0.7 0.3-1.3 .2
RCMD 230 36.4% 79 45.1% 1.3 0.8-2.1 .4
RCMD-RS 39 6.1% 12 6.9% 1.2 0.5-2.5 .7
5q2 syndrome 34 5.4% 15 8.6% 1.0 0.4-.26 .9
RAEB-1 74 11.7% 20 11.4% 0.7 0.4-1.5 .4
RAEB-2 0 0.0% 1 0.6%
MDS-U 20 3.2% 3 1.7% 0.6 0.2-2.4 .45
IPSS at inclusion ,1024
Low 332 55.5% 61 36.7%
Intermediate-1 266 44.5% 105 63.3%
BM blasts, % .1
#2 362 60.7% 85 51.8%
.2 to ,5 162 27.2% 51 31.1%
5-10 69 11.6% 28 17.1%
.10 3 0.5% 0 0.0%
Peripheral blasts, % .4
,1 477 75.5% 127 72.6%
$1 155 24.5% 48 27.4%
No. of cytopenias ,1024
0 132 20.9% 19 10.9% 1
1 332 52.5% 84 48.0% 1.3 0.7-2.4 .3
2 126 19.9% 46 26.2% 1.7 0.9-3.2 .1
3 42 6.7% 26 14.9% 2.4 1.1-5.2 .03
IPSS-R cytogenetic risk .5
Very good 64 11.2% 20 12.5%
Good 431 75.6% 112 70.0%
Intermediate 65 11.4% 24 15.0%
Poor/very poor 10 1.8% 4 2.5%
IPSS-R at inclusion .024
Very low 151 27.8% 29 19.7%
Low 238 43.7% 59 40.1%
Intermediate 118 21.7% 49 33.4%
High 32 5.9% 10 6.8%
Very high 5 0.9% 0 0%
Hb level, g/dL 10.2 9.3-11.4 9.5 8.5-10.7 ,1024 0.9 0.8-1.1 .2
RBC-TD at inclusion ,1024 .02
No 499 79.0% 102 58.3% 1
Yes 133 21.0% 73 41.7% 1.7 1.1-2.6
Platelets, 3109/L 184 108-277 155 89-261 .6
Neutrophils, 3109/L 2.4 1.5-3.9 2.1 1.2-3.8 .8
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95 patients with BM reassessment had progressed to IPSS-R high
or very high risk. Therefore, we sought to define a simple prognostic
index based on age, sex, baseline IPSS-R, and noninvasive
hematological parameters available at the 6-month visit, including
RBC-TD, absolute neutrophil and platelet counts at landmark, and
6-month relative neutrophil and platelet drops. In univariate analysis,
older age, RBC-TD, early platelet drop .25%, and lower platelet
value at landmark had significant adverse prognostic impact
(supplemental Table 3). Multivariate analysis after lasso penalized
regression18 identified older age (HR, 1.04; 95% CI, 1.02-1.05;
P , 1024), RBC-TD at landmark (HR, 2.8; 95% CI, 2.2-3.5;
P , 1024), and platelet drop . 25% (HR, 1.7; 95% CI, 1.3-2.2;
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Figure 1. Prognostic impact of relative drop in platelets and neutrophils. Kaplan-Meier plots of OS from landmark (with 95% CIs) according to 6-month relative
platelet (A) and neutrophil (B) drop. CIP since landmark according to 6-month platelet (C) and neutrophil (D) drop. Blue, relative platelet or neutrophil drop #25%; red,
relative platelet or neutrophil drop .25%.
Table 2. (continued)
Variable
Relative platelet drop
£25% (n 5 632) >25% (n 5 175)
P
Multivariate
n or median % or IQR n or median % or IQR OR 95% CI P
Treatment before landmark ,1024
ESA with or without G-CSF 205 32.4% 72 41.1%
G-CSF alone 3 0.5% 1 0.6%
HMA 8 1.3% 8 4.6%
HY 1 0.2% 2 1.2%
LEN 7 1.1% 15 8.6%
None 408 64.5% 77 44.0%
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P , 1024) as independent predictors of poor outcome. Of note,
replacing the global IPSS-R risk group with its individual components,
including baseline platelet count group (given the association
between baseline platelet count and 6-month platelet drop) also led
to the identification of RBC-TD at landmark and platelet drop .25%
as significant variables after lasso regression. Although platelet drop
was more frequent in patients with RBC-TD at landmark (41.5% vs
15.0% in those without RBC-TD; P, 1024), there was no significant
interaction between these 2 parameters (P 5 .19) and limited
collinearity in the multivariate model (mean variance inflation coefficient,
1.46). Therefore, we could design an age-independent 6-month
EUMDS classifier combining RBC-TD and platelet drop at landmark to
discriminate 3 groups with none (n5 504, 62%), 1 (n5 216, 27%), or
2 (n5 87, 11%) of these criteria, with significantly different 5-year
OS of 53.3% (95% CI, 46.4-59.8), 32.7% (95% CI, 23.5-42.2),
and 9.0% (95% CI, 2.7-20.0), respectively, after the 6-month
landmark (P , 1024; Figure 3A). The EUMDS 6-month classifier
was also predictive of CIP (P, 1024; Figure 3B). Importantly, the
EUMDS 6-month classifier successfully discriminated outcome in
each IPSS-R risk category (Figure 3C) and retained prognostic
value independently of the MD Anderson Prognostic Score for
lower-risk MDS (data not shown).22 Excluding the minority of
patients treated with HMAs, LEN, or HY prior to landmark, with or
without stratification on ESA treatment, did not affect these
conclusions, nor did exclusion of all 322 patients treated prior to
landmark (data not shown). The EUMDS classifier could also be
applied to the sensitivity cohort of 1610 patients (P , 1024),
where it could also discriminate outcome within each baseline
IPSS-R stratum (all P , 1024; supplemental Figure 5).
External validation of the 6-month EUMDS score
We next validated the 6-month EUMDS score in an indepen-
dent cohort from the Pavia Registry of lower-risk MDS. The
validation cohort included 335 lower-risk (IPSS low, n 5 182;
intermediate-1, n 5 153) MDS patients accrued since 1992, with
a follow-up visit at 6 6 1 month from diagnosis. Their detailed
characteristics at diagnosis and 6-month landmark are shown in
supplemental Table 4. The median interval from diagnosis to
landmark was 6.4 months. Eighty-seven (26%) patients had RBC-TD
at landmark. A platelet drop . 25% at landmark was found in
61 (18%) patients. With a median follow-up of 31.4 months after
landmark, the 5-year OS of those patients was 74.1% (95% CI,
55.2-86.0) compared with 86.0% (95% CI, 78.6-90.1) for those
with slower platelet decline (P , 1024; Figure 4A); 213 (63%),
96 (29%), and 26 (8%) patients had neither, 1, or both 6-month
EUMDS criteria. Their 5-year OS was 90.3% (95% CI, 82.5-94.8),
79.4% (95% CI, 64.2-88.7), and 30.3% (95% CI, 5.8-60.6),
respectively (P , 1024; Figure 4B). The EUMDS classifier also
successfully predicted CIP, with HR 5 2.9 (95% CI, 1.6-6.3) and
HR 5 5.0 (95% CI, 1.9-13.0) in patients with 1 and 2 criteria,
respectively (P 5 .0002; Figure 4C). Restricting analyses to the
273 patients diagnosed since 2000 led to similar conclusions
(data not shown).
Discussion
The prognosis of lower-risk MDS is heterogeneous.1 Early identifica-
tion of “lower-risk” MDS patients at risk for rapid progression should
rely on universal, affordable, and noninvasive tools to gain acceptance
in an elderly population often managed in community care centers.
The EUMDS registry provided a unique opportunity to address, for the
first time, the potential prognostic role of the dynamics of cytopenias in
lower-risk MDS.
We have identified a 25% platelet drop during the first 6 months
of lower-risk MDS diagnosis as an independent poor prognostic
feature in MDS. Combining early platelet drop with the presence of
RBC-TD after 6 months of follow-up allowed us to design a robust
cross-validated prognostic classifier that could be successfully
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Figure 2. Prognostic impact of relative platelet drop in
defined subgroups. Forest plot of HRs of relative platelet drop
.25% according to baseline IPSS-R risk and absolute platelet
count at inclusion and landmark.
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applied to all lower-risk MDS patients, regardless of IPSS-R risk
category. Sensitivity analyses confirmed the applicability of this
simple classifier even when follow-up visits were planned any time
during the first 10 months after diagnosis, thus capturing most
situations encountered in daily practice. This score was validated in
an independent cohort.
Dissecting the contribution of disease progression vs cytopenia-
specific complications remains challenging in MDS.6,23 Although
platelet drop increases bleeding risk,24-26 we believe that our
results support the contention that early platelet drop is a surrogate
of the global pace of MDS progression. We measured platelet
drop relative to baseline value, because an absolute drop does
not carry the same risk for bleeding, depending on baseline
platelet count. In multivariate analysis, relative platelet drop,
rather than steady-state platelet value at landmark, affected
prognosis. Relative platelet drop retained prognostic value even
in patients with platelets counts .50 3 109/L at landmark, a
threshold above which bleeding is infrequent. Finally, early platelet
drop also predicted a higher incidence of MDS progression.
Our findings resonate with previous reports that short-term
platelet changes induced by specific drugs instruct prognosis,
stressing that platelet kinetics is a good surrogate of BM failure
in MDS.27-29
Although early neutrophil drop had a prognostic impact on CIP,
it is likely that the prognostic impact of neutrophil drop is confounded
by inflammation or infection episodes. Platelet transfusions may con-
found assessment of platelet dynamics, possibly explaining the limited
prognostic value of platelets drop in patients already presenting with
,50 3 109/L platelets at inclusion. Treatments such as HY, HMAs,
and LEN can also induce thrombocytopenia; however, few patients
(5.1%) received these treatments during the 6 months following MDS
diagnosis, and excluding them did not change our results.
The stringent 6-month visit spacing recommended by the registry
was not realized in all patients; however, there was no correlation
between relative platelet drop and time to second evaluation. A
sensitivity analysis including all patients with a second visit within
10 months from inclusion (77% of patients) did not affect our
conclusions nor did considering the rate of platelet drop per month
in patients evaluated .6 months later.
Early platelet drop was only modestly linked to IPSS-R, suggesting
that dynamic parameters capture additional information. In fact,
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Figure 3. Design of the 6-month EUMDS classifier. Kaplan-Meier plots of OS (A) and CIP (B) from landmark according to the 6-month EUMDS classifier based on
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early platelet drop was tightly correlated to dyserythropoiesis,
as assessed by baseline Hb value and RBC-TD. Our study also
confirmed that RBC-TD is a key prognostic feature in lower-risk
MDS.6,30 Although correlated, early platelet drop.25% and RBC-TD
at 6 months from diagnosis could nevertheless be combined in a
simple EUMDS classifier, without significant interaction or collinearity.
This classifier could discriminate 3 groups of patients with different OS,
including a subgroup with RBC-TD and early platelet drop at 6 months
accounting for ;10% of “lower-risk” MDS patients, whose OS from
landmark did not exceed 2 years. Importantly, our classifier retained
its significance, regardless of the baseline IPSS-R risk category of
patients. We ensured the robustness of our model by basing variable
selection on penalized regression and by performing external validation
in an independent cohort from the Pavia Registry.6,12 Further validation
of this classifier in recently accrued cohorts receiving novel treatments
for lower-risk MDS will be required.
More sophisticated methodologies are required to describe patterns
in the trajectories of cytopenias in MDS31 and to determine whether
platelet drop can be used at any time of MDS evolution.32 Our
proposed EUMDS classifier nevertheless offers a simple universal
noninvasive and robust strategy to identify, early in the disease
course, the minority of “lower-risk” MDS patients who may require
close monitoring and potentially specific therapeutic interventions,
such as early start of HMAs or allogeneic stem cell transplantation.
Further studies, such as the ongoing prospective MDS-RIGHT
project, are required to determine whether somatic mutations induce
different kinetics of thrombocytopenia or whether they can be
combined with our EUMDS classifier to refine the prognostic
assessment of lower-risk MDS.
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